Harnessing Antitumor CD4+ T Cells for Cancer Immunotherapy

Cancers

卷:14

Romain Loyon¹  Syrine Abdeljaoued¹  Christophe Borg¹  Olivier Adotévi¹  Myriam Ben Khelil¹  Yann Godet¹ 

[1] UMR1098, EFS BFC, INSERM, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, University of Bourgogne Franche-Comté, F-25000 Besançon, France;

关键词: CD4⁺ T cells;    cancer immunotherapy;    immune checkpoint inhibitors;    adoptive cell transfer;    cancer vaccine;   

DOI  :  10.3390/cancers14010260

来源: DOAJ

【 摘 要 】

Over the past decades, CD4⁺ T cells have been considered as a supporting actor in the fields of cancer immunotherapy. Until recently, accumulating evidence has demonstrated the critical role of CD4⁺ T cells during antitumor immunity. CD4⁺ T cells can either suppress or promote the antitumor cytotoxic CD8⁺ T cell responses, either in secondary lymphoid organs or in the tumor. In this review, we provide an overview of the multifaceted role of different CD4⁺ T cell subsets in cancer immune response and their contribution during cancer therapies. Specifically, we focus on the latest progress regarding the impact of CD4⁺ T cell modulation on immunotherapies and other cancer therapies and discuss the prospect for harnessing CD4⁺ T cells to control tumor progression and prevent recurrence in patients.

【 授权许可】

Unknown